OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler SALT LAKE CITY, Nov. 12, 2024 (GLOBE ...
Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...
The ability to respond to changing surroundings was once considered exclusive to complex living organisms. Then came computers, specially designed for stimulus–response tasks, which can take in ...
Clinical-stage biotechnology firm Recursion announced the release of an open-source biological dataset, RxRx1, which the company has been building for more than five years. The dataset is composed of ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a Fast Company “Most Innovative Company” and leader in the artificial intelligence for drug discovery movement, today announced it will open-source a ...
Analysts and investors have been awaiting more proof that Recursion Pharma’s extensive and homegrown datasets can offer drug discovery platforms a speed-to-clinic edge. A $50 million investment the ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology company industrializing drug discovery, released its open-source RxRx19 dataset, which is the first human cellular morphological dataset ...
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results